<i>In vitro</i> characterisation of produced and purchased proteins.
Anja Sophie Schmid
Dario Neri
10.1371/journal.pone.0219313.g001
https://plos.figshare.com/articles/figure/_i_In_vitro_i_characterisation_of_produced_and_purchased_proteins_/9117383
<p>Cartoon, SDS-PAGE gel and SEC profile of (A) the noncovalent dimer F8IL15Rα in diabody format (predicted monomer molecular mass 44.4 kDa), (B) muIL15RαFc (predicted monomer molecular mass 44.9 kDa, manufacturer information: 80–90 kDa, 42 kDa and 35 kDa in reducing conditions), (C) huIL15RαFc (predicted monomer molecular mass 45 kDa, manufacturer information: 75–90 kDa in reducing conditions), (D) muIL15 biolegend (13.3 kDa), (E) muIL15 peprotech (13.3 kDa), (F) huIL15 (12.9 kDa) and (G) aIL15mAb. CHO = Chinese hamster ovary, mu = mouse, F8Dd = F8 diabody, hu = human, Fc = crystallisable fragment, m = marker, IgG = immunoglobulin G, nr = nonreducing conditions and red = reducing conditions.</p>
2019-07-26 17:25:05
SPR
size exclusion chromatography
surface plasmon resonance
IL 15-based biopharmaceuticals
IL 15R subunits
bind IL 15.
mouse IL 15R
mouse IL 15
F 8IL
IL 15
EDA
cancer therapy applications
SEC
IL 15 complexation
cell-based activity assay none
IL 15R fusions
novel interleukin -15 receptor
interleukin -15 complexation Interleukin -15
F 8 antibody
fusion protein F 8IL
IL 15R fusion proteins
fusion protein